Literature DB >> 21081944

Payers and the assessment of clinical utility for companion diagnostics.

B Quinn1.   

Abstract

The decision makers who approve or deny payment for health-care services review many new technologies. Reimbursement for companion diagnostics for expensive drugs ("personalized medicine") is already under close policy scrutiny, in line with long-standing concerns about overuse of diagnostic tests. Evaluation of diagnostic tests adds some complexities to the payer's comparative-effectiveness evaluation for drugs alone. Currently, decision-making frameworks suitable for companion diagnostics are being developed for practical application by payer policy makers.

Mesh：

Year:  2010        PMID： 21081944     DOI： 10.1038/clpt.2010.234

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  6 in total

1.  Non-invasive prenatal testing in mitigating concerns from invasive prenatal diagnostic testing: retrospective assessment of utility in an academic healthcare system in the US.

Authors:  Kibum Kim; Linda Kaitlyn Craft
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

2.  Olfactomedin 4 Serves as a Marker for Disease Severity in Pediatric Respiratory Syncytial Virus (RSV) Infection.

Authors:  H K Brand; I M L Ahout; D de Ridder; A van Diepen; Y Li; M Zaalberg; A Andeweg; N Roeleveld; R de Groot; A Warris; P W M Hermans; G Ferwerda; F J T Staal
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

3.  A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.

Authors:  Dee Luo; James A Smith; Nick A Meadows; A Schuh; Katie E Manescu; Kim Bure; Benjamin Davies; Rob Horne; Mike Kope; David L DiGiusto; David A Brindley
Journal:  Front Genet       Date:  2016-01-28       Impact factor: 4.599

Review 4.  Clinical Utility of Advanced Microbiology Testing Tools.

Authors:  Melissa B Miller; Faranak Atrzadeh; C A Burnham; Stephen Cavalieri; James Dunn; Stephen Jones; Charles Mathews; Peggy McNult; John Meduri; Chris Newhouse; Duane Newton; Michael Oberholzer; John Osiecki; David Pedersen; Nicole Sweeney; Natalie Whitfield; Joe Campos
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

5.  Use of MMP-8 and MMP-9 to assess disease severity in children with viral lower respiratory tract infections.

Authors:  Kim H Brand; Inge M L Ahout; Ronald de Groot; Adilia Warris; Gerben Ferwerda; Peter W M Hermans
Journal:  J Med Virol       Date:  2012-09       Impact factor: 2.327

Review 6.  Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).

Authors:  Philip Wahlster; Mireille Goetghebeur; Christine Kriza; Charlotte Niederländer; Peter Kolominsky-Rabas
Journal:  BMC Health Serv Res       Date:  2015-07-09       Impact factor: 2.655
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.